M. Habibian

发表

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.

S. Culine, S. Oudard, P. Marino, 2017, European journal of cancer.

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

S. Culine, N. Salem, M. Baciuchka, 2016, International journal of radiation oncology, biology, physics.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

A. Ravaud, S. Culine, J. Machiels, 2017, European urology.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

S. Culine, G. Deplanque, S. Oudard, 2016, European urology.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

A. Ravaud, J. Machiels, G. Deplanque, 2015, European urology.

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

S. Culine, C. Logothetis, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

S. Culine, Y. Allory, G. Gravis, 2021, Clinical genitourinary cancer.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

S. Culine, C. Logothetis, G. Le Teuff, 2017, European journal of cancer.

Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.

R. DiPaola, M. Carducci, M. Kohli, 2017 .

Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).

S. Guérif, R. de Crevoisier, C. Hennequin, 2015, Cancer treatment reviews.

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

R. DiPaola, M. Carducci, M. Kohli, 2018, European urology.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

A. Ravaud, S. Culine, G. Deplanque, 2015, The Lancet. Oncology.

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

B. Dubray, S. Guérif, A. Ruffion, 2016, The Lancet. Oncology.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

A. Ravaud, J. Machiels, B. Esterni, 2013, The Lancet. Oncology.

[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial].

K. Fizazi, P. Blanchard, G. Louvel, 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).

B. Esterni, S. Oudard, G. Gravis, 2010 .

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.

J. Dekker, H. Verheul, S. Oudard, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

S. Culine, C. Logothetis, G. Gravis, 2014, The Lancet. Oncology.

Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).

B. Dubray, J. Bachaud, S. Guérif, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.

G. Deplanque, S. Oudard, G. Gravis, 2015 .

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

S. Culine, G. Gravis, Anne-Laure Martin, 2014 .

A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.

J. Carles, A. Laplanche, K. Fizazi, 2014 .

Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.

G. Gravis, S. Chabaud, C. Chevreau, 2017 .

A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310).

S. Culine, L. Salomon, J. Bérille, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.